3175 results for «538»
3175 results
TAVI in small annulus - LIVE Case
11 Dec 2025 – From GulfPCR-GIM 2025
A 65-year-old female with obesity, diabetes mellitus, a history of stroke, atrial fibrillation, and RBBB on ECG, presented with symptomatic aortic stenosis and two-vessel coronary disease (OM and LAD, QFR: 0.70). Echocardiography and CT showed normal LV function (55%), a small annulus (370 mm²), and a...
Vascular interventions for the invasive cardiologist
11 Dec 2025 – From GulfPCR-GIM 2025
This session delivers a comprehensive overview of recent guideline changes in peripheral vascular disease and shares expert cardiologist experiences in various vascular interventions through case-based discussions. It also focuses on recognizing and managing peripheral vascular complications effectively to optimize patient outcomes.
Innovation and teamwork in structural heart interventions
11 Dec 2025 – From GulfPCR-GIM 2025
This session explores innovations and collaborative approaches in structural heart interventions, focusing on aortic and mitral valve procedures. It addresses procedural indications, challenges, and the evolving roles of non-physician allied professionals. Interactive elements foster knowledge exchange and support the growth of expertise in the structural heart...
Calcified lesions - LIVE Case
30 Jan 2026 – From SASCI-AfricaPCR
Watch this session if you want to understand the challenges and risks when treating calcified lesions, to learn how to accurately assess coronary calcification, to learn how to utilise the tools available for treating calcified lesions.
LIVE Case from Groote Schuur Hospital Cape Town
Left main bifurcation - LIVE Case
30 Jan 2026 – From SASCI-AfricaPCR
Join this session if you want to understand and optimise treatment strategies for LM bifurcation lesions, specifically: Understanding LM bifurcation anatomy and physiology, choosing the best stent strategy, optimising stent deployment and results.
LIVE Case from Groote Schuur Hospital Cape Town
Design that delivers the future of TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
This session presents the future of TAVI valve design, emphasizing supra-annular valve benefits, strategies for managing concomitant coronary artery disease, and redo-TAVI approaches tailored for long-term patient management.
Learn from the experts: Evolut first implant technique and treatment strategies
15 Feb 2026 – From PCR Tokyo Valves 2026
This expert-led session offers an in-depth review of evolving clinical practices in aortic valve disease treatment, emphasizing the potential of the transcarotid approach as a primary alternative access route. It compares current strategies including TAVI, surgical aortic valve replacement (SAV), TAV-in-SAV, and TAVI explantation, while addressing...
Learn from the experts: lifetime management for Evolut first redo TAVI (TAV-in-TAV) and explant
14 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an in-depth exploration of lifetime management strategies for patients undergoing Evolut first redo TAVI procedures, including TAV-in-TAV and explant techniques. It provides a comprehensive understanding of clinical decision-making algorithms, technical challenges, and key considerations for successful procedural planning and execution, supported by real-world...
TAVI today and tomorrow: international trends and future direction
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on the evolving landscape of TAVI, emphasising lifetime management strategies with a focus on the first valve implanted. It provides a comprehensive discussion on representative patient profiles, current guidelines from various countries, and future outlooks, alongside recent long-term clinical results for the balloon-expandable...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session develops a nuanced understanding of the complexity inherent in DMR cases, informed by the latest registry data. It highlights the capabilities of the PASCAL device in managing challenging anatomies and achieving predictable clinical results, alongside contemporary strategies for device selection and optimal placement to...
Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...
New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...
Built to last: lifetime management for durability and beyond
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the principles of lifetime management aimed at durability and optimal long-term outcomes in complex valvular heart disease cases. Key topics include the critical importance of initial valve choice, practical tips for optimizing paravalvular leak (PVL) management, and advanced strategies for redo transcatheter aortic...
The JenaValve Trilogy™ heart valve system in high surgical risk patients with symptomatic, severe aortic regurgitation: The ALIGN AR Trial
25 Oct 2023
Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)